382 related articles for article (PubMed ID: 17955251)
21. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.
Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
Calcif Tissue Int; 2010 May; 86(5):335-42. PubMed ID: 20309678
[TBL] [Abstract][Full Text] [Related]
22. Consultation corner. Bone loss drug gives users a break.
Bellantoni M
Johns Hopkins Med Lett Health After 50; 2007 Dec; 19(10):6. PubMed ID: 18225340
[No Abstract] [Full Text] [Related]
23. Yearly zoledronic acid in postmenopausal osteoporosis.
Poole KE; Kaptoge S; Reeve J
N Engl J Med; 2007 Aug; 357(7):711-2; author reply 714-5. PubMed ID: 17703530
[No Abstract] [Full Text] [Related]
24. [Postmenopausal osteoporosis. Bisphosphonates are not all equal].
MMW Fortschr Med; 2009 Mar; 151(11):46-7. PubMed ID: 19469206
[No Abstract] [Full Text] [Related]
25. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.
Huang WF; Tsai YW; Wen YW; Hsiao FY; Kuo KN; Tsai CR
Menopause; 2010; 17(1):57-63. PubMed ID: 19680161
[TBL] [Abstract][Full Text] [Related]
26. Zoledronic acid--once-yearly. Corticosteroid-induced osteoporosis: no benefit.
Prescrire Int; 2010 Apr; 19(106):63. PubMed ID: 20568485
[No Abstract] [Full Text] [Related]
27. Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats.
Maahs MP; Azambuja AA; Campos MM; Salum FG; Cherubini K
Head Neck; 2011 Feb; 33(2):199-207. PubMed ID: 20848442
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonates and atypical femoral fractures: a time for reflection.
Compston JE
Maturitas; 2010 Jan; 65(1):3-4. PubMed ID: 19932574
[No Abstract] [Full Text] [Related]
29. By the way, doctor. Should I take an intravenous drug for osteoporosis?
Robb-Nicholson C
Harv Womens Health Watch; 2007 Jul; 14(11):8. PubMed ID: 17665505
[No Abstract] [Full Text] [Related]
30. Pathological fractures in patients caused by bisphosphonate-related osteonecrosis of the jaws: report of 3 cases.
Wongchuensoontorn C; Liebehenschel N; Wagner K; Fakler O; Gutwald R; Schmelzeisen R; Sauerbier S
J Oral Maxillofac Surg; 2009 Jun; 67(6):1311-6. PubMed ID: 19446222
[No Abstract] [Full Text] [Related]
31. Bisphosphonates: a once-yearly treatment option with Reclast.
Van Gilder D
S D Med; 2008 Nov; 61(11):416-7. PubMed ID: 19066136
[No Abstract] [Full Text] [Related]
32. Do not use bisphosphonate therapy indefinitely for fracture prevention.
Prescrire Int; 2008 Oct; 17(97):214. PubMed ID: 19536944
[TBL] [Abstract][Full Text] [Related]
33. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
Prescrire Int; 2009 Dec; 18(104):247. PubMed ID: 20020572
[No Abstract] [Full Text] [Related]
34. Bisphosphonates and the risk of atrial fibrillation.
Sewerynek E; Stuss M
Endokrynol Pol; 2011; 62(1):93-6. PubMed ID: 21365587
[TBL] [Abstract][Full Text] [Related]
35. A once-yearly IV bisphosphonate for osteoporosis.
Obstet Gynecol; 2008 May; 111(5):1208-9. PubMed ID: 18448761
[No Abstract] [Full Text] [Related]
36. [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].
Dalle Carbonare L; Bertoldo F; Lo Cascio V
Reumatismo; 2009; 61(1):54-64. PubMed ID: 19370189
[TBL] [Abstract][Full Text] [Related]
37. Considering competing risks . . . Not all black and white.
Cauley JA; Ensrud KE
Arch Intern Med; 2008 Apr; 168(8):793-5. PubMed ID: 18443252
[No Abstract] [Full Text] [Related]
38. [An advantage for compliance: alendronate once weekly].
MMW Fortschr Med; 2005 Dec; 147(49-50):75. PubMed ID: 16401017
[No Abstract] [Full Text] [Related]
39. Yearly zoledronic acid in postmenopausal osteoporosis.
Chang JT
N Engl J Med; 2007 Aug; 357(7):713-4; author reply 714-5. PubMed ID: 17703528
[No Abstract] [Full Text] [Related]
40. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
Bize R; Lamy O; Peytremann-Bridevaux I
Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
